Merck & Co., Inc.
Merck Secures Japanese Approval for Subcutaneous Keytruda Combination
·Consolidated from 2 sources
Merck has received approval in Japan for a new subcutaneous formulation of its blockbuster cancer drug Keytruda, combined with an enzyme to aid absorption. This approval allows for all indications previously approved for Keytruda in Japan. The company is also anticipating key regulatory decisions from the FDA this week.
Merck & Co., Inc. announced today that its KEYTRUDA combination therapy, now branded as QLEX (pembrolizumab and berahyaluronidase alfa-pmph), has been approved in Japan. This novel formulation allows Keytruda to be administered subcutaneously, offering an alternative to intravenous infusions. The approval covers all indications for Keytruda that have previously been granted in Japan, potentially streamlining treatment for patients.
The subcutaneous administration is designed to improve convenience and accessibility for patients undergoing treatment with Keytruda, a widely used immunotherapy in oncology. This development marks a significant step in expanding the delivery options for one of Merck's flagship products. Further details on the rollout and availability of the QLEX formulation are expected.
In addition to the Japanese approval, Merck is currently awaiting important regulatory decisions from the U.S. Food and Drug Administration (FDA). This week is highlighted as a period of potential significant regulatory catalysts for the company, alongside other pharmaceutical firms. The outcomes of these FDA reviews could impact the future therapeutic landscape for several of Merck's products.
Sources
This recap was generated by consolidating the public headlines below.